Guardant Health, Inc / "Shield Post-Approval Study"

  • Study Sponsor and Protocol Number: 
    Guardant Health, Inc / "Shield Post-Approval Study" / 07-GI-003
  • Specialty:
    Oncology/Cancer Screening
  • Type:
    Post-Approval Study
  • Inclusion:
    Age 45-81 
    Considered as being "average risk" for Colorectal Cancer (CRC)
    Patient agrees to comply with study procedures and associated standards of care assessments (colonoscopy)
  • Exclusion:
    Undergoing a colonoscopy for the investigation of symptoms
    Personal history of CRC, defined as having one or more first-degree relatives (parent, sibling or child) diagnosed with CRC at any age
    Known diagnosis of inflammatory bowel disease

    •